Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus

ConclusionCana effectively improved the dysregulated glucose metabolism in patients with T2DM. This improvement can potentially be attributed to the restoration of balance among the gut, oral, and ocular surface microbial communities.Clinical trial registrationhttps://www.chictr.org.cn/showproj.html?proj=56487, identifier ChiCTR2000034878.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research